Lisa Lancaster, MD
Enriched profileChief Medical Officer, Endeavor BioMedicines · Endeavor BioMedicines
Lisa Lancaster is Chief Medical Officer, Endeavor BioMedicines at Endeavor BioMedicines. OpenAlex indexes 196 publications with 17,874 citations (h-index 51); ClinicalTrials.gov lists 5 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Pulmonary Disease profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Lisa H. Lancaster, MD, is Chief Medical Officer, Endeavor BioMedicines. The public record shows 196 publications with 17,874 citations (h-index 51), centered on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease (COPD) Research, Pulmonary Hypertension Research and Treatments. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 17 companies, 1 NIH-funded awards (2007–2008).
- Most recent indexed publication: 2022 · Advances in therapy
- Top research focus: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 90.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants
Sponsor: Endeavor Biomedicines, Inc.
- A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Sponsor: Endeavor Biomedicines, Inc.
Industry payments
Updated 14 Oct 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year202520 payments$14,840openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- United Therapeutics CorporationProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
57.4%Kinase inhibitor31.2%Ofev100%Part D<11 patientsPyridone26.2%Pirfenidone100%Part D≥13 patientsRespiratory
34%beta2-Adrenergic Agonist24.1%Albuterol Sulfate Hfa100%Part D<11 patientsAnticholinergic9.9%Incruse Ellipta100%Part D<11 patientsMetabolism & gastrointestinal
8.5%Proton pump inhibitor8.5%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2007–2008 per NIH RePORTER. The latest:
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD.
Advances in therapy
Review2022 - Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden.
Respirology (Carlton, Vic.)
Article2022 - Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis.
The open respiratory medicine journal
Article2020 - Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry.
BMJ open respiratory research
Article2020 - Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.
BMJ open respiratory research
Article2019
Most-cited works
by citation count (OpenAlex)Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/lisa-lancaster-md-87674e0f
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/lisa-lancaster-6395405
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
discoveries.vanderbilthealth.com/authors/lisa-lancaster-m-d
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →discoveries.vanderbilthealth.com ↗ - Other
endeavorbiomedicines.com/endeavor-biomedicines-appoints-internationally-renowned-ild-expert-lisa-lancaster-m-d-as-chief-medical-officer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →endeavorbiomedicines.com ↗ - Other
pulmonaryfibrosis.org/about-us/who-we-are/medical-advisory-committees/medical-advisory-board
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pulmonaryfibrosis.org ↗ - ResearchGate
researchgate.net/scientific-contributions/Lisa-Lancaster-14184867
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗ - LinkedIn
LinkedIn: Lisa Lancaster - Professor Pulmonary Medicine, Physician, Researcher and Budding Entrepreneur
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vanderbilthealth.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vanderbilthealth.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vanderbilthealth.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vanderbilthealth.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vanderbilthealth.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vanderbilthealth.com ↗
Editorial & leadership roles
journal and society appointments- Steering Committee member
Diffuse Lung Disease Network, American College of Chest Physicians
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →endeavorbiomedicines.com ↗ - Steering Committee member
Pulmonary Fibrosis Foundation Registry
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →endeavorbiomedicines.com ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine (former, transitioned to CMO role at Endeavor BioMedicines April 2025)
Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.vumc.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Marshall University
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital